GBP2 Antibody

What is GBP2 and what is its biological significance?

GBP2 belongs to the large GTPases superfamily and is induced by interferon-gamma (IFN-γ). It plays an essential role in host natural and autonomous cellular immunity and has been implicated in various disease processes, particularly tumorigenesis . The protein consists of 591 amino acids with a molecular weight of approximately 67 kDa . GBP2 functions primarily through interactions with immune signaling pathways, particularly the JAK-STAT pathway, making it a critical component of the cellular immune response .

GBP2 demonstrates context-dependent functions across different tissues and disease states. For instance, while it inhibits migration in breast cancer cells, it facilitates invasion in glioma cells, highlighting its complex and sometimes contradictory roles in disease progression .

In which tissues and cell types is GBP2 typically expressed?

GBP2 expression has been detected in multiple tissue types and shows significant variability between normal and pathological states. According to antibody validation data, GBP2 protein is consistently detected in:

GBP2 expression is upregulated in multiple cancers, including glioblastoma multiforme (GBM), renal clear cell carcinoma (KIRC), renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), and thyroid carcinoma (THCA) . Additionally, it shows high expression in activated microglia, particularly the M1 phenotype, which is relevant in neuroinflammatory conditions .

How does GBP2 contribute to tumor immune microenvironment?

GBP2 plays a significant role in shaping the tumor immune microenvironment across various cancer types. Research indicates that GBP2 expression correlates strongly with immune cell infiltration patterns within tumors .

Patients with high GBP2 expression demonstrate increased infiltration of multiple immune cell types, as validated through sophisticated Opal multiplex immunohistochemistry in clear cell renal cell carcinoma (ccRCC) tissues. Specifically:

• Increased infiltration of CD3+ T cells (general T lymphocytes)

• Higher numbers of CD8+ T cells (cytotoxic T lymphocytes)

• Greater infiltration of CD68+ macrophages

• Enhanced presence of cells expressing immune checkpoint markers PD-1 and CTLA4

This immune-hot phenotype associated with GBP2 overexpression has been observed across multiple cancer types. GBP2 expression positively correlates with tumor-infiltrating immune cells (TIICs), including NK cells, T cells, dendritic cells, and neutrophils, though correlations with B cells, CD4+ T cells, and macrophages vary by cancer type .

Gene enrichment analyses reveal that genes positively correlated with GBP2 are enriched in interferon-γ response, allograft rejection, and interferon-α response pathways, further supporting its role in immune modulation within the tumor microenvironment .

What is the prognostic significance of GBP2 expression in different cancer types?

GBP2 expression demonstrates distinct prognostic implications across cancer types, with considerable variability in its association with survival outcomes:

This variability highlights the context-dependent role of GBP2 in cancer progression. A five-protein prognostic signature incorporating GBP2 has been developed for ccRCC, demonstrating its value as part of multifactorial prognostic tools .

The dichotomy between GBP2's apparent tumor-promoting effects in most cancers versus its association with better prognosis in gastric cancer underscores the importance of context-specific analysis when evaluating GBP2 as a biomarker .

How does GBP2 relate to immunotherapy response prediction?

GBP2 has emerged as a promising predictor of immunotherapy response across multiple cancer types. Research indicates that GBP2 expression is positively associated with established immunotherapy biomarkers and correlates with clinical response to immune checkpoint inhibitors .

Key findings regarding GBP2 and immunotherapy include:

• GBP2 expression positively correlates with PD-L1 expression, CD8+ T cell abundance, and PD1+ cell abundance, as validated through immunohistochemical analysis

• GBP2 is negatively correlated with mismatch repair (MMR) gene expressions (MLH1, MSH2, MSH6, and PMS2), suggesting a potential relationship with microsatellite instability, a known predictor of immunotherapy response

• GBP2 overexpression is observed in gastric cancer tumors with favorable immunotherapeutic response

• GBP2 can predict immunotherapeutic responses in at least four different cancer types: melanoma, urothelial carcinoma, non-small cell lung cancer, and breast cancer

These findings suggest that GBP2 expression could serve as a pan-cancer biomarker for identifying patients likely to benefit from immunotherapy approaches, particularly immune checkpoint inhibitors.

What are the optimal protocols for GBP2 detection in immunohistochemistry?

For optimal GBP2 detection in immunohistochemistry applications, researchers should consider the following validated protocol parameters:

Tissue Preparation and Antigen Retrieval:

• Recommended section thickness: 4 μm

• Deparaffinization: Use xylene followed by rehydration

• Antigen retrieval options:

  • Primary recommendation: TE buffer (pH 9.0) in a pressure cooker, boiling for 2.5 minutes

  • Alternative method: Citrate buffer (pH 6.0)

• Peroxidase quenching: Treat sections with 3% hydrogen peroxide

• Blocking: Use appropriate blocking buffer to prevent non-specific binding

Antibody Application:

• Primary antibody dilution range: 1:50-1:500 for IHC applications

• Incubation conditions: Overnight at 4°C for primary antibody

• Detection system: Standard secondary antibody system with appropriate chromogen

Controls and Validation:

• Positive control tissues: Human spleen tissue has been validated for positive detection

• Negative controls: Omission of primary antibody or use of isotype control

For multiplex immunohistochemistry applications involving GBP2 and immune cell markers (such as CD3, CD8, CD68, PD-1, and CTLA4), Opal multiplex immunohistochemistry has been successfully employed to evaluate co-expression patterns and spatial relationships between GBP2 and immune infiltrates .

How should researchers optimize Western blot protocols for GBP2 detection?

For successful Western blot detection of GBP2, researchers should follow these recommendations:

Sample Preparation:

• Validated sample types: A375 cells, HeLa cells, mouse spleen tissue, rat spleen tissue

• Expected molecular weight: 67 kDa

Antibody Parameters:

• Recommended dilution range: 1:500-1:2000 for Western blot applications

• Storage buffer considerations: PBS with 0.02% sodium azide and 50% glycerol pH 7.3

• Storage conditions: -20°C, stable for one year after shipment; aliquoting is unnecessary for -20°C storage

Protocol Optimization:

• It is recommended that researchers titrate the antibody in each testing system to obtain optimal results, as the optimal dilution may be sample-dependent

• For specific Western blot protocols optimized for GBP2 detection, specialized protocols are available from antibody manufacturers

What approaches are effective for studying GBP2 function through gene modulation?

Several approaches have been validated for modulating GBP2 expression to study its function:

RNA Interference:

• Short hairpin RNA (shRNA) targeting GBP2 has been successfully employed to downregulate GBP2 expression in microglia

• This approach has demonstrated functional consequences of GBP2 downregulation, including effects on mitochondrial function in microglia and reduced neuronal damage in co-culture systems

Functional Readouts for GBP2 Modulation:

• Mitochondrial function assessment following GBP2 knockdown

• Cytokine production measurement via ELISA (IL-6, TNF-α, IL-10) to assess inflammatory responses

• Cell death analysis using flow cytometry with FITC Annexin V Apoptosis Detection Kit to quantify apoptosis in co-culture systems

• JAK/STAT pathway activation assessment to evaluate downstream signaling effects

Experimental Design Considerations:

• Co-culture systems are particularly valuable for studying GBP2's role in cell-cell interactions, such as microglia-neuron or tumor-immune cell interactions

• When studying GBP2 in cancer contexts, consideration of both cell-autonomous effects and effects on the tumor microenvironment is essential

How can GBP2 be leveraged as a biomarker in cancer diagnostics and treatment planning?

GBP2 shows considerable promise as a biomarker in several aspects of cancer management:

Prognostic Applications:

• GBP2 has been incorporated into a five-protein prognostic signature for clear cell renal cell carcinoma, demonstrating its value in multiparameter prognostic tools

• High GBP2 expression correlates with poor survival outcomes in multiple cancer types, making it a potentially valuable indicator of aggressive disease

Immunotherapy Response Prediction:

• GBP2 expression is a promising pan-cancer biomarker for estimating tumors' immunological characteristics and may be utilized to detect immuno-hot tumors, particularly in gastric cancer

• GBP2 has demonstrated predictive value for immunotherapeutic responses in at least four different cancer types: melanoma, urothelial carcinoma, non-small cell lung cancer, and breast cancer

• Strong correlation with established immunotherapy biomarkers (PD-L1, CD8+ T cells, PD1+ cells) further supports its value in this context

Implementation Considerations:

• For clinical applications, immunohistochemical detection of GBP2 can be performed using validated antibodies at recommended dilutions (1:50-1:500)

• Correlation with other immune markers may enhance the predictive value of GBP2 testing

• Integration into existing diagnostic workflows should consider tissue-specific optimization and appropriate controls

What is the potential of GBP2 as a therapeutic target in neurodegenerative diseases?

Recent research has unveiled GBP2 as a promising therapeutic target for inflammation-related neurodegenerative diseases:

Rationale for GBP2 Targeting:

• GBP2 is highly expressed in the brains of dementia mice and in brain disorders such as Alzheimer's disease

• GBP2 exhibits high expression in M1 microglia, which are associated with pro-inflammatory responses in the brain

• Downregulation of GBP2 in activated microglia has demonstrated anti-inflammatory effects

Experimental Evidence:

• Studies using shRNA-mediated GBP2 knockdown in microglia have shown:

  • Altered mitochondrial function in microglia

  • Reduced neuronal damage in co-culture systems compared to control groups

  • Modulation of inflammatory cytokine production

Therapeutic Development Considerations:

• Targeting strategies might include RNA interference approaches, similar to the experimental shRNA models used in research

• Assessment of therapeutic efficacy should include measures of neuroinflammation, neuronal viability, and cognitive outcomes in preclinical models

• Potential for combination therapy with existing anti-inflammatory approaches should be explored

This emerging evidence suggests that GBP2 inhibition may represent a novel therapeutic strategy for neurodegenerative diseases characterized by chronic neuroinflammation, though additional research is needed to fully validate this approach for clinical development.

How should researchers address inconsistent results when studying GBP2 across different cancer models?

GBP2 demonstrates context-dependent functions that can vary dramatically between cancer types. When encountering inconsistent results across different cancer models, researchers should consider:

Biological Factors:

• Tissue context variations: GBP2 inhibits migration in breast cancer but facilitates invasion in glioma, highlighting tissue-specific functions

• Immune microenvironment differences: The composition of immune infiltrates can substantially modify GBP2's impact

• Prognostic implications vary: High GBP2 expression correlates with poor prognosis in most cancers but better prognosis in gastric cancer

Experimental Approaches to Resolve Inconsistencies:

• Perform comprehensive immune profiling alongside GBP2 analysis to contextualize findings within the immune microenvironment

• Consider JAK/STAT pathway activation status, as GBP2 functions through this signaling axis

• Validate findings across multiple model systems (cell lines, primary cells, animal models, and human specimens)

• Employ both gain-of-function and loss-of-function approaches to fully characterize GBP2's role in specific contexts

What are the key considerations for validating GBP2 antibody specificity?

Ensuring antibody specificity is crucial for generating reliable data about GBP2. Researchers should implement these validation strategies:

Technical Validation Approaches:

• Positive controls: Use tissues known to express GBP2, such as human, mouse, or rat spleen tissue

• Knockdown/knockout validation: Confirm antibody specificity using GBP2 knockdown or knockout samples

• Multiple antibody validation: Compare results using antibodies targeting different epitopes of GBP2

• Western blot validation: Confirm specific detection at the expected molecular weight (67 kDa)

Application-Specific Considerations:

• For IHC applications: Optimize antigen retrieval methods, with TE buffer pH 9.0 recommended as primary choice and citrate buffer pH 6.0 as an alternative

• For Western blot: Consider sample-dependent optimization of antibody dilution within the recommended range (1:500-1:2000)

• For functional studies: Validate GBP2 modulation at both protein and mRNA levels

These comprehensive validation approaches help ensure that experimental findings truly reflect GBP2 biology rather than antibody artifacts or off-target effects.